Clostridioides difficile infection in a long-term convalescence hospital: A real tale of pitfalls and outdated therapy by Esteban-Rihuete, M. et al.
Rev Esp Quimioter 2021;34(1): 51-55 51
ISSN: 0214-3429 / ©The Author 2020. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Revista Española de Quimioterapia 
doi:10.37201/req/085.2020
Infección por Clostridioides difficile en un 
hospital de convalecencia: una historia real de 
trampas y tratamiento anticuado
RESUMEN
Objetivo. Conocer las características y factores de riesgo 
de infección por Clostridioides difficile (ICD) en un hospital de 
convalecencia es clave para mejorar su manejo.
Material y métodos. Estudio retrospectivo con 37 pa-
cientes, durante 43 meses. Describimos variables demográficas, 
datos clínicos, tiempo hasta el diagnóstico, el tratamiento y la 
evolución.
Resultados. Análisis de 46 episodios (37 pacientes, edad 
media=82,2 años). 77,8% tenían dependencia absoluta, 41,7% 
enfermedad renal crónica, 64,9% habían recibido antibióticos 
en los 3 meses previos, 40,5% recibían antibióticos en el mo-
mento del diagnóstico. Fue el primer episodio en 78,4%, y la 
primera recidiva en 21,6%. En el 89,2% se comenzó tratami-
ento en las primeras 24 horas tras el diagnóstico, mayoritar-
iamente metronidazol. El 83,3% se recuperaron. 3 pacientes 
murieron por ICD. El diagnóstico figuraba en el informe de alta 
en 91,1%.
Conclusiones. El tratamiento antibiótico previo, un alto 
grado de dependencia, y el fracaso renal, fueron los factores de 
riesgo principales. Hay margen de mejora en el manejo de ICD 
en nuestro hospital.
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ABSTRACT
Objective. The aim of the study was to know the char-
acteristics and risk factors of Clostridioides difficile infection 
(CDI) in a long-term hospital is key to improve its manage-
ment.
Material and methods. Retrospective study with 37 pa-
tients, along 43 months. We describe demographic variables, 
clinical data, time to diagnosis, treatment, and evolution.
Results. Analysis of 46 episodes (37 patients, mean 
age=82.2 years). 77.8% were absolutely dependent, 41.7% had 
chronic kidney disease, 64.9% had received antibiotics in the 
previous three months, 40.5% received antibiotics at diagnosis. 
It was the first episode in 78.4%, and first recurrence in 21.6%. 
Therapy was started in the first 24 hours after diagnosis in 
89.2%, mostly metronidazole. 83.3% recovered, 3 patients died 
from CDI, diagnosis was registered in the discharge report in 
91.1%.
Conclusions. Previous antibiotic therapy, high grade of 
dependency and renal failure were the main risk factors. There 
is room for improvement in CDI management at our hospital.
Keywords Clostridium difficile, Clostridioides difficile, nosocomial infec­
tion, recurrent infection, management.
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rence after an initial episode (21.6%), 8 as second recurrence, 
and 1 as third recurrence (overall, 17 episodes in 12 patients). 
Data concerning the characteristics of the infection (clinical 
data, treatment, evolution) appear in Table 2.
In 15 patients with CKD and age > 65 years, CDI was qual-
ified as severe, with a high risk of recurrence according to the 
guidelines. 
The anti-CDI therapy of the first episode was metroni-
dazole in 24/29 (82.8%), vancomycin in 4/29 (13.8%), and fi-
daxomicin in one. The first CDI recurrence was treated with 
metronidazole in 5 cases, and with vancomycin in 3 cases. The 
second CDI recurrence was treated with metronidazole in 1 
case, vancomycin 2 cases, fidaxomicin 1 case. The third recur-
rence received fidaxomicin. 
DISCUSSION
We describe in this study the characteristics of 37 patients 
with CDI in a long term-acute care hospital, trying to confirm 
if the well-known reported risk factors are also present in our 
patients, and if the diagnostic and therapeutic approaches 
employed fit with current guidelines. Most studies have been 
performed in health facilities of very different profile (tertiary 
hospitals [8,9], multicentric studies [10], or extensive epidemi-
ological studies [2]). After a thorough bibliographical search, 
we have not found any study performed in a hospital of our 
profile. 
In our series, almost 60% of patients came from emer-
gency departments of other hospitals, for convalescence and/
or rehabilitation after infections or cerebrovascular disease. As 
symptoms may be scarce or not reported, and given the high 
index of dependency in this population, diagnosis may be a 
difficult challenge. It is also worth mentioning, as it has been 
reported in other series [10], the association between CDI and 
chronic renal insufficiency (15 from 36 patients, 41.7%, had 
an eGFR<50mL/min). All these factors confer to our patients a 
high degree of frailty and a high risk of CDI recurrence, a find-
ing also previously described [8,11,12]. We also found in our 
patients a wide use of PPIs, drugs that modify the pH of the 
bowel and disrupt bowel microbiota, as well as an association 
of CDI with previous antibiotic use, also described in previous 
studies [3,4,8-11]. It is important to remark that 40.5% of pa-
tients were on antibiotics at the time of diagnosis, and they 
were withdrawn in only 53.5% of them, which may indicate a 
pitfall in the management of CDI in our patients. 
Concerning clinical presentation, most (83.8%) patients 
did not refer any symptoms or signs. This scarcity of clinical 
data indicates that CDI is clinically silent in this population, 
even in severe cases. Though there are no registered data re-
garding the number of leukocytes, applying the GEIH Score 
[12] (age, number of diarrhoeal episodes and renal insufficien-
cy), 40.5% of patients had severe CDI, with a high risk of re-
currence.
Regarding the analysis of the episodes, in 78.4% of cases 
CDI presented as the first episode. In 21.6% of cases, the epi-
INTRODUCTION
Clostridioides difficile infection (CDI) is the most frequent 
cause of nosocomial diarrhoea. It is a global health problem, 
with most cases acquired in hospital but also described in the 
community. Reported mortality rate ranges between 3-15%, 
and recurrence rate, 12-40% [1,2].
Hospital San Juan de Dios (HSJD) is a long term-acute care 
hospital with 188 beds, holding units of palliative care, neu-
rorehabilitation, haemodyalisis for chronic patients, convales-
cence, and an acute geriatric unit. Patients are admitted from 
acute care hospitals of the region, and directly from nearby 
centres of primary care, with a catchment area of 500.000 in-
habitants. These types of health facilities have their own fea-
tures and challenges concerning CDI [3,4].
MATERIAL AND METHODS
We have performed a retrospective study of all CDI cas-
es since 5th May 2016 to 31st December 2019. We used the 
definitions of nosocomial, community-acquired and recurrent 
CDI reported in updated guidelines [5,6]. In every patient with 
a clinical picture suggestive of CDI (diarrhoea, abdominal pain, 
fever), a faecal sample was collected and analysed at the mi-
crobiology laboratory of the hospital, using C. difficile quik 
check complete (Techlab® Blacksburg) test. This is a fast mem-
brane enzyme-immunoassay which simultaneously detects the 
bacterial antigen glutamate dehydrogenase (GDH) and also 
toxins A and B. Samples which were GDH+/Tox- were sent to 
the reference hospital (Hospital Miguel Servet) for Polymer-
ase Chain Reaction –PCR- testing (GenXpert®Cepheid), which 
detects a toxin-producer gen [7]. Data obtained from clinical 
records were fully anonymised and collected using a specif-
ically designed database. For the statistical study, qualitative 
variables are presented according to distribution of frequen-
cies, and expressed as number and percentage. Quantitative 
variables are presented as means, median, mode and stand-
ard deviation. We did all statistical analysis using SPSS (IBM 
SPSS Statistics 25.0 2017). The Ethics Committee of Clinical 
Research of Aragón (CEICA) approved the study project (ruling 
31/01/2020), as did the Ethics Committee of HSJD.
RESULTS
Patients, risk factors and clinical data. We describe 37 
patients diagnosed of CDI during the study period (24 men/13 
female), mean age 82.8 +/- 9.6 years (56-100). Patient´s de-
mographics and clinical data before and on admission appear 
in Table 1.
CDI diagnosis, treatment and clinical outcome. (Table 
2) There were 46 episodes of CDI (29 first episodes and 17 re-
currences). In 29 patients (78.4%) the infection was the 1st ep-
isode, and in 8 cases (21.6%), the debut episode in our hospital 
was the first recurrence of CDI. 12 patients out of the 37 pre-
sented recurrent CDI during their hospital stay: 8, first recur-
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and 30% in the study by Lessa et al. [2] and similar in other 
studies [8,11]; it is reported as high as 57.1% in one of the 
studies performed in Spain [11].
In most cases, treatment was started within the same 
day or the following day after reception of the laboratory di-
agnosis, which can be a good quality indicator. Considering 
sode during hospital stay was a recurrence, as the initial epi-
sode had happened previously. According to the current defi-
nition of recurrence given by IDSA-SHEA [6], it can be said that 
32.4% suffered from recurrent CDI, and 67.5% (n=25), only an 
initial episode of CDI, without further recurrences during the 
length of the hospital stay. This recurrence rate is between 20 
























































Days of disease that led to admission Mean ± SD =17.8 ± 21.2











Barthel on admission Mean ± SD =15.8 ± 24.4*
CKD 15/36* 41.7%*
PPIs 29/37 78.4% 
Table 1  Patients´ demographics, clinical data before and on admission.
CKD=chronic kidney disease, (estimated Glomerular Filtration Rate<50mL/min); PPIs=proton pump inhibitors.  
*Data about clinical outcome was missing in one patient.
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Variable Number (n)   Percentage (%)





















































Initial episode during hospital stay






Recurrent CDI 12/37 32.4%
Treatment










Contact precautions 26/37 70.3%
Evolution until discharge
Recovery 31/36* 86.1%*
Derivation to other center 1/37 2.7%
Death attributable to CDI 3/37 8.11%
Days of hospital stay Mean ± SD = 43.6 ± 30.0
Days diagnosis-discharge Mean ± SD = 23.0 ±19.2
Microbiological control 4/37 10.8%
CDI as principal diagnosis in discharge report 7/37 18.9%
CDI specified in discharge report 34/37 91.9%
Table 2  Clinical data of CDI, treatment and evolution until discharge.
CDI = Clostridiodes difficile infection; * Data about clinical outcome was missing in one patient.
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therapeutic approach, 78.4% of individuals with an initial epi-
sode were treated with metronidazole, which was the drug of 
choice until 2017. However, last guidelines [5,6] advise about 
the use of vancomycin or fidaxomicin as first line in all pa-
tients with first episode of CDI [13-15]. So, it could be said that 
the degree of penetrance of current therapeutic guidelines is 
poor in our hospital. Recurrent episodes were also treated in-
adequately, mostly with metronidazole again.
Despite this, 83.8% of the patients recovered, a similar 
high rate is reported by Aljafel et al. [9] and others [8] 8.1% 
of deaths in our series were attributable to CDI. This figure is 
similar to the rate reported by Olsen et al. [15] and also by 
Lessa et al. [2] and it is even higher in other series [1,8,10]. It is 
worthwhile to remember that all publications belong to health 
facilities with very different characteristics from our hospital. 
Mean hospital stay of our patients was 43.6 days (standard de-
viation: 30.1 days), which is longer than the duration reported 
by other authors [8,9]
We acknowledge the limitations of the study: retrospec-
tive, with a small sample, and patients who are far from rep-
resentative of the general population, as are aged (mean age 
82 years) and with multiple comorbidities. It means that CDI is 
bound to be more severe and the risk of recurrences, higher. 
However, it has also strengths: it can inspire further research 
about CDI in the hospital, within the frame of a stewardship 
team and infection control approach. Moreover, it analyses a 
type of patients which is specific to this profile of hospitals, 
scarcely represented in current literature.
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